Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Leonardo BrunettiDipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0002-7787-6639
Fabio FrancavillaDipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0009-0004-3921-7597
Mauro NisoDipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0002-2846-1744
Jakub Kosma FrydrychLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Kraków, Poland.ORCID 0009-0009-2704-5712
Ewa TrojanLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Kraków, Poland.ORCID 0000-0002-9573-7026
Igor A SchepetkinDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.
Liliya N KirpotinaDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.
Beata GrygierLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Kraków, Poland.
Krzysztof ŁukowiczLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Kraków, Poland.
Mark T QuinnDepartment of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.ORCID 0000-0001-8114-5073
Agnieszka Basta-KaimLaboratory of Immunoendocrinology, Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna St., 31-343 Kraków, Poland.ORCID 0000-0002-3109-0040
Enza LacivitaDipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0003-2443-1174
Marcello LeopoldoDipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari Aldo Moro, via Orabona 4, 70125 Bari, Italy.ORCID 0000-0001-8401-2815
Funding
Research Core (Developmental Research Project Program)P20GM103474 · NIGMS · MONTANA STATE UNIVERSITY - BOZEMAN · PI Ann Therese Bertagnolli · 2012 to 2026
$60.0M
Alzheimer's Association AARG-NTF-18-565227Ministry of University and Research (MUR) MNESYS (PE0000006)Ministry of University and Research (MUR) PRIN P20227TATANational Institutes of Health IDeA Program GM103474National Science Centre, grant no. 2021/43/B/NZ4/01133, Tasks 1, 2 (OPUS22)NIGMS NIH HHS P20 GM103474
6 · The paper itself
Abstract
Chronic neuroinflammation and oxidative stress play an important role in the onset and progression of neurodegenerative disorders, including Alzheimer's disease, which can ultimately lead to neuronal damage and loss. The mechanisms of sustained neuroinflammation and the coordinated chain of events that initiate, modulate, and then lead to the resolution of inflammation are increasingly being elucidated, offering alternative approaches for treating pathologies with underlying chronic neuroinflammation. Here, we propose a new multitarget approach to address chronic neuroinflammation and oxidative stress in neurodegenerative disorders by activating the formyl peptide receptor 2 (FPR2) combined with the potentiation of hydrogen sulfide (H
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.